Coh Bar, Inc. CWBR
We take great care to ensure that the data presented and summarized in this overview for CohBar, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CWBR
View allLatest Institutional Activity in CWBR
Top Purchases
Top Sells
About CWBR
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Insider Transactions at CWBR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2022
|
Joseph J. Sarret Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
131,017
+46.45%
|
$0
$0.15 P/Share
|
|
Aug 01
2022
|
Jeffrey Francis Biunno CFO, Treasurer and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
26,203
+31.36%
|
$0
$0.15 P/Share
|
|
Nov 01
2021
|
Nir Yacov Barzilai Director |
BUY
Open market or private purchase
|
Direct |
13,889
+0.27%
|
-
|
|
Nov 01
2021
|
David Greenwood Director |
BUY
Open market or private purchase
|
Direct |
20,000
+33.33%
|
-
|
|
Oct 28
2021
|
Misha Petkevich Director |
BUY
Open market or private purchase
|
Indirect |
167,000
+29.06%
|
$0
$0.58 P/Share
|
|
Aug 18
2021
|
Joseph J. Sarret Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$20,000
$1.12 P/Share
|
|
Aug 18
2021
|
Jeffrey Francis Biunno CFO, Treasurer and Secretary |
BUY
Bona fide gift
|
Indirect |
4,000
+44.44%
|
-
|
|
Aug 18
2021
|
Jeffrey Francis Biunno CFO, Treasurer and Secretary |
SELL
Bona fide gift
|
Direct |
4,000
-11.38%
|
-
|
|
Aug 11
2021
|
Kenneth C Cundy Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-50.0%
|
$20,000
$2.01 P/Share
|
|
Aug 11
2021
|
Kenneth C Cundy Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+33.33%
|
$0
$0.73 P/Share
|
|
Feb 16
2021
|
Kenneth C Cundy Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-50.0%
|
$10,000
$1.9 P/Share
|
|
Feb 16
2021
|
Kenneth C Cundy Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+33.33%
|
$0
$0.73 P/Share
|
|
Dec 18
2020
|
Jeffrey Francis Biunno CFO, Treasurer and Secretary |
BUY
Open market or private purchase
|
Direct |
7,490
+29.98%
|
-
|
|
Dec 18
2020
|
Jon Leland Stern Director |
BUY
Open market or private purchase
|
Direct |
99,861
+12.9%
|
-
|